Impact of COVID-19 restrictions on thyroid cancer diagnoses in a comprehensive cancer center (2017–2023)
Age- and sex-adjusted annual incidence of thyroid cancer declined steadily from 2017 to 2022. The annual decrease in thyroid cancer continued through the pandemic years. Tumor size and mortality remained stable across all years evaluated. The increase in diagnoses noted in 2023 may be a correction due to missed cases during the years of the pandemic or could represent a new steady state incidence after years of decline.
Authors
- Hayley Mann (ORCID: https://orcid.org/0000-0003-0640-1617)
- Yanchen Zhang (ORCID: https://orcid.org/0000-0003-1756-1077)
- Erin J. Aiello Bowles (ORCID: https://orcid.org/0000-0001-6287-7391)
- Abdullah Adil
- David O. Francis (ORCID: https://orcid.org/0000-0003-1064-5892)
- Yichi Zhang (ORCID: https://orcid.org/0000-0001-5730-9648)
- Natalia Arroyo
- Erin Dimon
- Oguzhan Alagoz
- Louise Davies
- Sara Fernandes-Taylor
Institutions
- Dartmouth College (US)
- Dartmouth Institute for Health Policy and Clinical Practice (US)
- University of Wisconsin–Madison (US)
- Kaiser Permanente Washington Health Research Institute (US)
- Madison Area Technical College (US)
- University of Michigan (US)
- University of Wisconsin Carbone Cancer Center (US)
- Michigan United (US)
- White River Junction VA Medical Center (US)
- Wisconsin Division of Public Health (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1371/journal.pone.0340347
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00